Open access
Open access
Powered by Google Translator Translator

Oncology – Urological

Single-arm Phase 1b/2 study | Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer.

21 Sep, 2022 | 13:10h | UTC

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer – Journal of Clinical Oncology

Commentary: High ORR Associated With Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Cancer – Cancer Network

 


RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.

19 Sep, 2022 | 12:31h | UTC

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 


ASCO Rapid Recommendation | Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer.

19 Sep, 2022 | 12:31h | UTC

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation – Journal of Clinical Oncology

 


Cohort Study | Long-term outcomes among men undergoing active surveillance for prostate cancer.

15 Sep, 2022 | 13:11h | UTC

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden – JAMA Network Open

Invited Commentary: Exploring the Long-term Outcomes of Active Surveillance Among Men With Prostate Cancer—Best for Whom? – JAMA Network Open

 


RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.

11 Sep, 2022 | 22:52h | UTC

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial – The Lancet Oncology

Commentaries:

Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology

Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News

 

Commentary on Twitter

 


RCT | Adjuvant atezolizumab fails to improve outcomes in patients with renal cell carcinoma at increased risk of recurrence following resection.

11 Sep, 2022 | 22:28h | UTC

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentaries:

Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times

IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News

 

Commentary from the author on Twitter (thread – click for more)

 


30-month follow-up analysis of a RCT | Pembrolizumab vs. placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma.

5 Sep, 2022 | 14:20h | UTC

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology

Invited Commentary: Adjuvant immunotherapy for renal cell carcinoma – The Lancet Oncology

Original Article: Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma – New England Journal of Medicine

 


RCT | Telaglenastat failed to improve the efficacy of Cabozantinib in patients with advanced renal cell carcinoma.

5 Sep, 2022 | 14:19h | UTC

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


Phase 2 RCT | Adjuvant intravesical chemohyperthermia not better than passive chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer.

25 Aug, 2022 | 12:00h | UTC

Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial – European Urology

 

Commentary on Twitter

Under a Creative Commons license

 


M-A | Androgen receptor signaling inhibitors in addition to Docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

24 Aug, 2022 | 13:58h | UTC

Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis – European Urology

 


Phase 2 RCT | Biomarker-selected maintenance Poly ADP-Ribose Polymerase inhibition with Rucaparib following chemotherapy for metastatic urothelial carcinoma.

15 Aug, 2022 | 11:42h | UTC

A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma – Journal of Clinical Oncology

 


Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.

11 Aug, 2022 | 11:54h | UTC

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes – JAMA Network Open

 

Commentary on Twitter

 


Guideline | Androgen deprivation therapy: adverse events and management strategies.

3 Aug, 2022 | 14:15h | UTC

UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text) – Canadian Urological Association Journal

 


Retrospective cohort study | Sequential Intravesical Gemcitabine and Docetaxel seem effective for high-risk BCG-naïve nonmuscle-invasive bladder cancer.

2 Aug, 2022 | 11:58h | UTC

Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin–Naïve High-Risk Nonmuscle-Invasive Bladder Cancer – Journal of Urology

Commentary: Intravesical chemotherapy combination provides effective treatment alternative for high-risk non-muscle invasive bladder cancer – Wolters Kluwer

 


Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.

29 Jul, 2022 | 12:23h | UTC

Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer – JAMA Network Open

 

Commentary on Twitter

 


Cohort Study | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients.

28 Jul, 2022 | 13:13h | UTC

Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study – The Aging Male

News Release: Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease – Taylor & Francis

 


Guidelines on the diagnosis and treatment of prostate cancer.

20 Jul, 2022 | 12:11h | UTC

The Swedish national guidelines on prostate cancer – Scandinavian Journal of Urology

Editorial: A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease

Part 1: Early detection, diagnostics, staging, patient support and primary management of non-metastatic disease

Part 2: Recurrent, metastatic and castration resistant disease

 


Updates on enhanced recovery after surgery for radical cystectomy.

20 Jul, 2022 | 12:03h | UTC

Updates on enhanced recovery after surgery for radical cystectomy – Therapeutic Advances in Urology

Related:

Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations – Clinical Nutrition

Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines

Top 100 Most-Cited Articles on Enhanced Recovery After Surgery: A Bibliometric Analysis and Visualized Study – Frontiers in Surgery

 


Guidelines on germline testing for urologic tumor syndromes.

15 Jul, 2022 | 12:49h | UTC

Guidelines on Germline Testing for Urologic Tumor Syndromes – European Urology Focus

 


How to treat renal cell carcinoma: the current treatment landscape and cardiovascular toxicities.

14 Jul, 2022 | 12:35h | UTC

How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities – JACC: CardioOncology

Related: Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis – The Journal of Urology

 


Genetic testing in prostate cancer management: considerations informing primary care.

13 Jul, 2022 | 11:25h | UTC

Genetic testing in prostate cancer management: Considerations informing primary care – CA: A Cancer Journal for Clinicians

 


Single-arm Study | Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation.

11 Jul, 2022 | 11:56h | UTC

Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)

Commentary: Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers — Trial’s 6-month rate of 6% was superior to historical control – MedPage Today (free registration required)

Related: Small study shows feasibility of MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer

 

Commentary on Twitter

 


RCT | Orteronel for metastatic hormone-sensitive prostate cancer.

8 Jul, 2022 | 11:18h | UTC

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) – Journal of Clinical Oncology

Commentary: Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer – HealthDay

 

Commentary on Twitter

 


Consensus Statements | Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in patients with prostate cancer and with respect to [177Lu] Lu-PSMA radioligand therapy.

6 Jul, 2022 | 11:39h | UTC

EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy – European Urology Oncology


Network M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.

6 Jul, 2022 | 11:09h | UTC

High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.